These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19434587)

  • 1. [Therapeutic use of tetrabenazine].
    López Del Val LJ; López-García E; Martínez-Martínez L; Santos-Lasaosa S
    Rev Neurol; 2009 May 16-31; 48(10):523-33. PubMed ID: 19434587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrabenazine.
    Fasano A; Bentivoglio AR
    Expert Opin Pharmacother; 2009 Dec; 10(17):2883-96. PubMed ID: 19929707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J; Clarence-Smith K
    Expert Rev Neurother; 2011 Nov; 11(11):1509-23. PubMed ID: 22014129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrabenazine for the treatment of tardive dyskinesia.
    Leung JG; Breden EL
    Ann Pharmacother; 2011 Apr; 45(4):525-31. PubMed ID: 21487088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.
    Sahin T; Yilmaz R; Akbostanci MC
    Parkinsonism Relat Disord; 2020 May; 74():36-37. PubMed ID: 32311641
    [No Abstract]   [Full Text] [Related]  

  • 10. An experimental model for Huntington's chorea?
    Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y
    Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.
    Jankovic J
    Ann Neurol; 1982 Jan; 11(1):41-7. PubMed ID: 6460467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders.
    Toglia JU; McGlamery M; Sambandham RR
    J Clin Psychiatry; 1978 Jan; 39(1):81-7. PubMed ID: 147268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J; Shi WX; Dashtipour K
    Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J; Orman J
    Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Adv Neurol; 1983; 37():277-89. PubMed ID: 6574695
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Hunter C; Jankovic J
    Mov Disord; 2007 Jan; 22(2):193-7. PubMed ID: 17133512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrabenazine (Xenazine) for Huntington's chorea.
    Med Lett Drugs Ther; 2009 Jan; 51(1304):7-8. PubMed ID: 19172140
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs.
    Ondo WG; Jong D; Davis A
    J Child Neurol; 2008 Apr; 23(4):435-7. PubMed ID: 18192650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrabenazine treatment in movement disorders.
    Paleacu D; Giladi N; Moore O; Stern A; Honigman S; Badarny S
    Clin Neuropharmacol; 2004; 27(5):230-3. PubMed ID: 15602104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.